- Home
- FEBO vs PSTV Comparison
FEBO vs PSTV Comparison
Compare FEBO & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- PSTV
- Stock Information
- Founded
- FEBO 1993
- PSTV 1996
- Country
- FEBO Hong Kong
- PSTV United States
- Employees
- FEBO N/A
- PSTV N/A
- Industry
- FEBO
- PSTV Medical/Dental Instruments
- Sector
- FEBO
- PSTV Health Care
- Exchange
- FEBO Nasdaq
- PSTV Nasdaq
- Market Cap
- FEBO 13.5M
- PSTV 12.2M
- IPO Year
- FEBO 2023
- PSTV N/A
- Fundamental
- Price
- FEBO $1.40
- PSTV $0.47
- Analyst Decision
- FEBO
- PSTV Strong Buy
- Analyst Count
- FEBO 0
- PSTV 3
- Target Price
- FEBO N/A
- PSTV $12.75
- AVG Volume (30 Days)
- FEBO 5.9K
- PSTV 3.1M
- Earning Date
- FEBO 05-27-2025
- PSTV 05-23-2025
- Dividend Yield
- FEBO N/A
- PSTV N/A
- EPS Growth
- FEBO N/A
- PSTV N/A
- EPS
- FEBO N/A
- PSTV N/A
- Revenue
- FEBO $17,110,653.00
- PSTV $5,824,000.00
- Revenue This Year
- FEBO N/A
- PSTV $13.26
- Revenue Next Year
- FEBO N/A
- PSTV $8.84
- P/E Ratio
- FEBO N/A
- PSTV N/A
- Revenue Growth
- FEBO 9.01
- PSTV 18.54
- 52 Week Low
- FEBO $0.93
- PSTV $0.24
- 52 Week High
- FEBO $17.68
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- FEBO 62.78
- PSTV 39.86
- Support Level
- FEBO $1.30
- PSTV $0.48
- Resistance Level
- FEBO $1.49
- PSTV $0.75
- Average True Range (ATR)
- FEBO 0.11
- PSTV 0.10
- MACD
- FEBO 0.01
- PSTV -0.00
- Stochastic Oscillator
- FEBO 76.92
- PSTV 5.95
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).